http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#Head
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#assertion
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#provenance
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#pubinfo
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#assertion
http://purl.obolibrary.org/obo/DOID_1067
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1067
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00484
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
http://www.w3.org/2000/01/rdf-schema#label
brimonidine tartrate ophthalmic solution 2 is indicated for lowering intraocular pressure iop in patients with open angle glaucoma or ocular hypertension the iop lowering efficacy of brimonidine tartrate ophthalmic solution diminishes over time in some patients this loss of effect appears with a variable time of onset in each patient and should be closely monitored brimonidine tartrate ophthalmic solution 2 is an alpha adrenergic agonist indicated for lowering intraocular pressure iop in patients with open angle glaucoma or ocular hypertension 1
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00484
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#provenance
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#pubinfo
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig
http://purl.org/nanopub/x/hasSignature
EqYUYVwpVNOxvbwCXyqfXwbx5yEghlnNGvJTws+02x6ovYy+bgnWRp3myIc/nExV6gpAr4RVQAc0HwbdnNAICYU/wpr5WcymiMX/dNnGD7QygRs3EPUjXMfA1eKHoaW7gPGkCrsYRQ7kveQMrY5NuYNbdEXJPuK2Uow/1LtDaaI=
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://purl.org/dc/terms/created
2021-06-13T12:21:17.724+02:00
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAJmaktIbKjebVp7qY-6OO7R6OgGe47xC4hnmR3CGpbIc
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs